Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.

In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for adults 50 and older than a currently available shot.

The shot also showed strong efficacy against each of the major influenza strains in the shot, including A/H1N1, A/H3N2 and the B/Victoria lineages.

Efficacy appeared consistently strong........

© The Hill